Get started
Author

Xinquan Liang

Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
2020 · Li Xuan, Yu Wang, et al. · The Lancet Oncology · 343
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
2023 · Li Xuan, Yu Wang, et al. · The Lancet Haematology · 88
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
2023 · Hua Jin, Yu Zhang, et al. · Journal of Hematology & Oncology · 79
PDF
Effect of sorafenib on the outcomes of patients with FLT3‐ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation
2018 · Li Xuan, Yu Wang, et al. · Cancer · 62
PDF
Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial
2022 · Haiyan Zhang, Zhiping Fan, et al. · Journal of Clinical Oncology · 58
Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia
2017 · Qian Fan, Hui Liu, et al. · Journal of Hematology & Oncology · 46
PDF
Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia
2022 · Guangyang Weng, Yu Zhang, et al. · Journal of Internal Medicine · 44
Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
2019 · Li Xuan, Yu Wang, et al. · Transplantation and Cellular Therapy · 33
A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort study
2020 · Hui Liu, Li Xuan, et al. · Leukemia · 26
Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation
2016 · Xinmiao Jiang, Lanping Xu, et al. · OncoImmunology · 26
PDF
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD: A multicenter phase 2 study
2023 · Sijian Yu, Yu Zhang, et al. · Journal of Internal Medicine · 25
The effect of granulocyte-colony stimulating factor, decitabine, and busulfan–cyclophosphamide versus busulfan–cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial
2023 · Li Xuan, Min Dai, et al. · The Lancet Haematology · 25
Haploidentical Peripheral Stem Cell Transplantation for Young Patients with Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide and Methotrexate
2021 · Kaitai Yang, Susu Gong, et al. · Transplantation and Cellular Therapy · 24
Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study
2023 · Ruoyang Shao, Yu Zhang, et al. · Signal Transduction and Targeted Therapy · 19
PDF
Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
2024 · Guopan Yu, Yu Zhang, et al. · Clinical Cancer Research · 17
PDF
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial
2023 · Yiwen Ling, Li Xuan, et al. · Journal of Clinical Oncology · 17
Retrospective cohort study comparing the outcomes of intravenous busulfan vs. total-body irradiation after single cord blood transplantation
2019 · Baolin Tang, Xiaoyu Zhu, et al. · Bone Marrow Transplantation · 14
A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia
2022 · Xiaoxia Chen, Junwei Huang, et al. · Cancer · 13
Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia
2024 · Zhao Yin, Zurong Yao, et al. · Journal of Cancer Research and Clinical Oncology · 10
PDF
Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial
2022 · Xin Xu, Zhiping Fan, et al. · BMC Medicine · 7
PDF
Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT
2025 · Rongtao Xue, Min Dai, et al. · Blood Cancer Journal · 6
PDF
A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre‐transplantation for Ph + acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study
2024 · Hui Liu, Hui Xu, et al. · American Journal of Hematology · 4
Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax‐based therapy
2024 · Guangyang Weng, Jingya Huang, et al. · Cancer Medicine · 4
PDF
Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study
2025 · Yiling Ye, Xinyu Liu, et al. · British Journal of Haematology · 3
Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study
2023 · Guangyang Weng, Jingya Huang, et al. · Annals of Hematology · 3
Works count: 53
Citation count: 1,006
H-index: 16
I10-index: 19
Year
Topic
Type